GSK’s two-speed pipeline strategy reflects a calculated attempt to balance innovation with risk mitigation, but its long-term viability hinges on execution and market differentiation. The strongest version of this narrative credits GSK for leveraging external partnerships to diversify its early-stage pipeline while reserving larger investments for assets with clearer biological validation. This approach aligns with industry trends toward de-risking R&D through targeted acquisitions and data-driv...